Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group

The advancement of infectious disease diagnostics, along with studies devoted to infections caused by gram-negative and gram-positive bacteria, is a top scientific priority of the Antibacterial Resistance Leadership Group (ARLG). Diagnostic tests for infectious diseases are rapidly evolving and improving. However, the availability of rapid tests designed to determine antibacterial resistance or susceptibility directly in clinical specimens remains limited, especially for gram-negative organisms. Additionally, the clinical impact of many new tests, including an understanding of how best to use them to inform optimal antibiotic prescribing, remains to be defined. This review summarizes the recent work of the ARLG toward addressing these unmet needs in the diagnostics field and describes future directions for clinical research aimed at curbing the threat of antibiotic-resistant bacterial infections. Accurate diagnostics are a critical part of the fight against antibacterial resistance. The Antibacterial Resistance Leadership Group has prioritized support for the development and evaluation of new tests or test strategies designed to optimize use of antibiotics and improve patient outcomes.